Monday, April 18, 2016

BRIEF-Bioinvent says multiple myeloma phase II study of antibody BI-505 ready to start

* Multiple myeloma phase II study of Bioinvent's antibody

BI-505 ready to start

Source text for Eikon:

Further company coverage:

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)